<DOC>
	<DOCNO>NCT02228785</DOCNO>
	<brief_summary>This study design investigate safety tolerance three dos ( 100µg , 200µg , 500µg ) G17DT treatment patient colorectal cancer .</brief_summary>
	<brief_title>A Study Safety Tolerance Three Doses G17DT Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Patients age 18 year histologically verify adenocarcinoma colon rectum . Recurrent metastatic disease amenable curative surgery and/or radiotherapy . Life expectancy great 3 month . Karnofsky Index Score great equal 50 % . Written inform consent obtain . Neoplastic lesion colorectal cancer ( except treat basal cell carcinoma skin cancer uterine cervix , Stage I . Acute intercurrent illness . Patient consider medical risk nonmalignant systemic disease grossly abnormal laboratory result . Patients receive anticancer therapy within 3 month . Factor liable alter serum gastrin concentration affect intragastric acidity , instance concomitant therapy H2 receptor antagonist drug , proton pump inhibitor , previous gastric surgery . Patients immunologically compromise include corticosteroid therapy . Women childbearing age . Positive immediate hypersensitivity reaction skin test study medication . Patients unable complete diary book Haematogical Status Haemoglobin count le 10g/dL White Blood Cell count le 4.0 x 10^9/L Platelet count le 100 x 10^9/L</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>